HRZ to break even at $39 per barrel: 88 Energy

|

Published 17-JUN-2016 15:08 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

88 Energy (ASX:88E) has revealed the oil price it would need for development of the HRZ shale in Alaska: $39/bbl – well below the current West Texas Intermediate crude price of about $50/bbl.

Releasing a presentation to investors this morning, 88E said the oil price required for development ranged from $27/bbl at the low cost end up to $68/bbl at the upper echelon.

The $39/bbl however is the mid-case for development of the shale.

The new estimate comes ahead of the spudding of the Icewine-2 horizontal well, which is targeting the HRZ, in the first quarter of next year – a target 88E said it was on target to hit.

The above estimates are based on the assumption of a successful flow test at Icewine-2.

Having a pre-drill break-even price below the current price of oil though, can be read as a broad positive for the company.

In other 88E news, it said 2D seismic it took earlier this year over a section of the HRZ was on course to be processed and interpreted in August.

The excitement around Icewine-2 has been building since a slew of positive technical data has built the case during the year, and DeGolyer and MacNaughton released an updated resource estimate of up to 1.4 billion barrels of recoverable oil equivalent – based on technical data from Icewine-1.

Internal estimates, however, had that figure at 3.6 billion barrels.

Before Icewine-1 was drilled, D&G said the play had recoverable potential of 492 million barrels on a gross mean unrisked basis.

88E will be hoping positive flow data from Icewine-2 may trigger another look at the numbers.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X